로딩 중…
지수 로딩 중…
Bicara Therapeutics Inc. Common Stock
BCAX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$25.74-5.02%
2026-08-03
Financials
Valuation Metrics
Bicara Therapeutics Inc. Common Stock's Market Cap is $1.69B. At end of 2025 it was $928M. Ranked #2171 of 3,112 in US market (top 70%), #851 of 1,445 on NASDAQ (top 59%), #153 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.69B | US#2,171/3,112 Sec#153/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-157M | US—/3,112 Sec—/269 |
| Total Assets | $554M | US#2,706/3,112 Sec#143/269 |
| Net Assets | $514M | US#2,241/3,112 Sec#112/269 |
| Value | ||
| P/B | 3.29x | US#1,784/3,112 Sec#99/269 |
| FCF Yield | -6.89% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -30.61% | US#2,621/3,112 Sec#128/269 |
| ROA | -28.42% | US#2,863/3,112 Sec#159/269 |
| Financial Health | ||
| Debt Ratio | 7.71% | US#76/3,112 Sec#34/269 |
| Total Debt | $1M | US#2,918/3,112 Sec#239/269 |
| FCF | $-117M | US#2,616/3,112 Sec#163/269 |
| Cash | $323M | US#1,373/3,112 Sec#75/269 |
| Current Ratio | 13.85x | US#177/3,112 Sec#59/269 |
| Performance | ||
| 1Y Return | 144.44% | US#191/3,112 Sec#59/269 |
| 1M Return | -11.24% | US#2,664/3,112 Sec#177/269 |
| From 52W High | -16.94% | US#1,537/3,112 Sec#94/269 |
| 1Y MDD | -36.21% | US#1,755/3,112 Sec#121/269 |
| Trading | ||
| Volume | 385,852 shares | US#2,245/3,112 Sec#219/269 |
| Trading Value | $10M | US#2,333/3,112 Sec#188/269 |
| Per Share | ||
| EPS | $-2.50 | US—/3,112 Sec—/269 |
| BPS | $7.28 | US#2,009/3,112 Sec#97/269 |